anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Introduction: Across the healthcare continuum, patients with low functional health literacy may have worse outcomes due to difficulties in following prescribed medication regimens. While reasons for non-adherence can be drawn from the intra-personal, interpersonal, and systemic perspectives; one starting point is the difficulty that patients have reading and understanding medication instructions on a prescription bottle labels. Labels can provide a vital reminder and decision support aid for patients and healthcare proxies. Yet, skills must be available for reading and understanding the labels. The investigators will utilize "Talking Pill Bottles" to record prescription medication instructions so that patients can re-play the instructions as needed in their homes. Purpose: The aim of this research project is to compare the use of "Talking Pill Bottles" to usual care in patients who have low functional health literacy and who purchase medications for primary hypertension at a retail pharmacy with regard to: a. feasibility of the procedures, b. utility of the equipment, c. medication adherence, d. self efficacy in medication self management, and e. blood pressure control. Design: This novel intervention will be tested within the context of a retail pharmacy in the Pacific Northwest. The pilot test will use a randomized trial design with two research arms. Analysis: Within-group change scores on a self efficacy measure and blood pressures will be examined with the paired t-test; between group measures will also be examined between the two treatment arms. The investigators will also track medication complexity as a potential confounder and conduct semi-structured exit interviews. Conclusion: Results will help establish the feasibility and utility of providing this technology to patients who have low functional health literacy in a retail pharmacy. The investigators will gather preliminary descriptive data along with variance and effect size measures for power estimations in a future multi-site, randomized controlled trial.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, particularly to urology, and can be used for treating chronic prostatitis and prostate adenoma. For this purpose, for three days in the morning 30-40 minutes before meals and in the evening after meals in 30-40 minutes, one teaspoon of celandine juice dissolved in 150-200 ml of water is taken. From the fourth day, for seven days in the morning and in the evening under the same scheme, one table spoon of celandine juice dissolved in 100 ml of water is taken, and additionally, a prepared mixture of sage and camomile tea in the ratio 1:1 and celandine juice in the ratio: a mixture in the form of three table spoons of sage and chamomile tea taken in the ratio 1:1, and one table spoon of celandine juice are introduced through rectum. ^ EFFECT: method allows relieving prostate inflammation effectively and preventing adenoma malignification with ensured prolonged and reliable remission due to normalisation of metabolic processes in a body. ^ 2 ex
PROBLEM TO BE SOLVED: To obtain an ophthalmic preparation having such characteristics such as mitigation of poisoning due to ophthalmic surgery, by adding a specified amount of a specific hyaluronic acid (salt) to a system containing a citrate, antioxidant and phosphate buffering agent. SOLUTION: This ophthalmic preparation is obtained by adding 1.5-3.5w/v% of hyaluronic acid (salt) as a thickening agent 1000000-2000000 dalton in molecular weight to a system containing a citrate, at least one antioxidant tolerant for intraocular tissue and a phosphate buffering agent. This ophthalmic preparation has a viscosity of 18000-41000cps at 25 deg.C at 2sec<-1> . The antioxidant is e.g. an ascorbate, glucose, cysteine (derivative therefrom), sulfide, water-soluble antioxidant, peptide. The concentration of the antioxidant is pref. 0.01-1.0wt.%, 0.04-4.0wt.%, or 0.01-0.05wt.%, for sodium ascorbate, glucose, or citrate, respectively. Besides, the above system may be incorporated with sodium chloride, etc.
The invention relates to hybrid systems comprising the components polyvinylpyrrolidone and/or the copolymers thereof and dimethyl sulfoxide. The invention further relates to polymer matrices that contain said hybrid systems, to transdermal therapeutic systems based on said polymer matrices and to the production thereof. The hybrid system allows to introduce otherwise hardly soluble, pharmaceutically active substances, e.g. ibuprofen, into an nonpolar matrix. The system is advantageous in that polar active substances can be dissolved in a nonpolar matrix such as e.g. polyisobutene beyond the saturation point. The hybrid system also prevents the crystallization of the active substance, thereby allowing for a continuous release of the active substance over the entire lifetime of a transdermal therapeutic system, such as a plaster.
The present invention discloses a medicine for treating asthma and a producing method thereof. The medicine for treating asthma is prepared from a persimmon extract, rock candy, loquat flowers, orange peel, fructus momordicae, American ginseng and pure Kaoliang spirit by weight. The producing method mainly adopts a soaking method. The medicine for treating asthma has obvious effect on the treatment of tracheitis and asthma. Compared with the existing medicines for clearing away phlegm and relieving cough and asthma, the medicine for treating asthma has the advantages of conspicuous curative effect, no toxic side effect and wide application range. Besides, the medicine for treating asthma has conspicuous curative effect on cough caused by common cold and smoke phlegm of longtime smokers.
Systems, methods, devices, and applications for managing a binge eating disorder (BED). A smartphone and server application may be provided for monitoring and treating BED. Ecological Momentary Assessment (EMA) may be used for automated and/or manual acquisition of data related to triggers associated with BED. Risk factors may be captured in real-time to provide data to both patients and clinicians. For manual data acquisition, the user may be prompted to input emotional states, urges to binge, eating behavior, and binge episodes. For automated acquisition, time, place (e.g. via GPS), medicine adherence, and physical activity may be recorded. The user may be provided with alerts and/or interventions when it is determined that they are at risk of binging.
Nitric oxide gas at 160 ppm inhaled four times daily for 30 min delivered with air as the carrier via nasal inhalation for a total of 7.5 days. Total dose of 2400 ppm hours.
This invention relates to methods of formulating steroid pheromones as novel stable emulsions. These emulsions can be used for administration of the steroid pheromones to living organisms such as humans or pigs in place of current organic solvent or pressurized aerosol formulations that present hazards in both shipping and application. Uses relating to pigs are in stimulation of sexual maturation, diagnosis of the onset and timing of oestrus in female pigs, and inducing boars to accept dummy sows. The water-based emulsions can include 5 -androst-16-en-3-one and 3 -hydroxy-5a-androst-16-ene for administration to pigs. The use of water-based emulsions eliminates the need for formulation of the steroid pheromones in organic solvents, delivery of these pheromones as pressurized aerosols, and following the precautions required to reduce hazards during shipping and handling. The water-based emulsions allow for treatment of living organisms where a liquid organic solvent formulation or aerosol of the pheromones might be harmful to the organism or a substrate.
Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.
This is an observational, prospective (study following participants forward in time), multi-center (study conducted in more than 1 center) study to identify the predictive factors that will effectively predict the response to erythropoietin treatment in cancer related anemia participants receiving chemotherapy. The entire duration of study will be approximately 1 year. Participants will primarily be evaluated for achieving at least 1 gram per deciliter (g per dl) rise in hemoglobin (substance that carries oxygen and gives blood its red color) level after receiving erythropoietin treatment based on National Comprehensive Cancer Institute (NCCN) V3.2009 practice guideline criteria. Response to erythropoietin treatment will also be predicted using other independent hematological (related to blood) factors like C-reactive protein (CRP - is an acute serum protein released from liver). It is associated with low hemoglobin \[substance that carries oxygen and gives blood its red color\] or erythropoietin \[hormone secreted by kidney that helps in formation of red blood cells in bone marrow\] resistance), erythropoietin (EPO), hemoglobin, hematocrit (amount of red blood cells in blood), reticulocyte (immature red blood cells) count, ferritin (a protein that stores iron and allows the body to use iron), serum iron (iron is in the blood which is bound to transferrin) and transferring iron binding capacity (TIBC), level. Number of blood transfusions and participants' safety will be monitored throughout the study.
Nick is a 5-year-old boy who began displaying self-stimulating behaviors and decreased social interactions shortly before turning 3 years. At the age of 3.5 years, he was diagnosed with autism spectrum disorder by a local developmental-behavioral pediatrician. His parents recall that the physician described Nick to be "high functioning" and encouraged them to expect that he would attend college and live independently as an adult. Upon receiving the diagnosis, intervention was initiated using an applied behavioral analysis (ABA) approach. With this intervention, he demonstrated initial gains in the use of complex language and improved social interactions.Concerns regarding suspected psychosis emerged just before starting kindergarten when Nick began experiencing ego-dystonic visual and auditory hallucinations. Initially, Nick verbally responded to the hallucinations and vividly described what he was experiencing. Shortly after the onset of these hallucinations, Nick experienced a significant decrease in the frequency and complexity of his expressive language and became more withdrawn. Over time, his hallucinations intensified, and his parents became increasingly fearful for his safety. Various antipsychotic and mood-stabilizing medications, steroids, and immunotherapy have been trialed with limited improvement of his symptoms.An extensive medical evaluation yielded the following:1. Magnetic resonance imaging of the brain: dilated perivascular spaces.2. Urine organic acids: ketosis and increased lactic acid.3. Antinuclear antibody: minimally positive.4. Vitamin B12: elevated.All other studies, including lumbar puncture, electroencephalogram (awake and asleep), genetic studies (chromosomal microarray, fragile X testing, and whole exome sequencing), metabolic studies, inflammatory markers, and thyroid panel, were negative/normal.Nick is enrolled in a special education classroom within a school that utilizes an ABA-based approach for all students. As part of his educational programming, he receives 25 hours of ABA in a 1:1 setting, 2 hours of speech therapy, 3 hours of occupational therapy, 1 hour of physical therapy, and 30 minutes of music therapy weekly. Current concerns include significant head-banging and thrashing before falling asleep, hyperactivity, unsafe behaviors (e.g., banging on windows, climbing high to reach desired items), aggression toward caregivers, limited ability to complete self-care tasks (e.g., personal hygiene, toileting), significant decline in expressive language, and continued response to internal stimuli.Nick's parents now present to a multidisciplinary center seeking guidance regarding additional therapies/interventions to assist in management of his current developmental and behavioral challenges as well as information regarding his expected developmental trajectory as he reaches adulthood.
A text message sent 7 days prior then 48 hours before a booked/timed appointment. The content of the message will be the 'usual care' content that is currently sent by the London Breast Cancer Screening Programme. This includes a link to a YouTube hosted video.
Provided is a method for evaluating urate transport-related disease factor and inflammation-related disease factor, in which a high-capacity urate transporter is identified in order to assist in the early treatment and prevention of urate transport-related disease and inflammation-related disease on the basis of the identified transporter. Also provided are an evaluation kit which implements this method, a test sample, and a drug. A urate transporter capable of selectively and ATP-dependently emitting urate is formed from proteins having ABCG2. The method for evaluating urate transport-related disease factor and inflammation-related disease factor comprises a step for detecting variations in genes that encode the ABCG2 protein using a sample containing the human genes of the subject. When a subject has an SNP of V12M, R113X, Q126X, Q141K, F208S, G268R, E334X, S441N, L447V, S486N, F506SfsX4, R575X, and/or C608X, it can be concluded that the subject has a factor that is capable of inducing urate transport failure, or a state or disease attributable to that failure. When a subject has an SNP of V12M, it can be concluded that, unlike the other SNPs, there is a possibility that the subject does not possess such a factor because, although this variation itself does not lead to a change in urate transport capability, said variation is related to linkage disequilibrium with other SNPs.
A 3-year-old boy initially presented with purpura-like rashes and nephrotic syndrome, suspected to be IgA vasculitis nephritis (IgAVN). The suggestion of kidney biopsy was rejected. Although the patient responded well to glucocorticoids, they later developed recurrent proteinuria, refractory diarrhea, and subsequent metabolic acidosis. Kidney biopsy showed membranous nephropathy with positive semaphorin 3B expression, indicative of other kidney diseases rather than IgAVN. Although his kidney responded well to glucocorticoid combined with cyclosporine A treatment regimen, enteropathy and severe food allergy still progressed afterwards as evidenced by villous atrophy on gastrointestinal endoscopy examination. Whole exome sequencing identified a heterozygous missense variant in exon 11 of FOXP3: c.1121 T > G, confirming the diagnosis of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. The case expanded the phenotypic spectrum of IPEX syndrome, suggesting high phenotypic heterogeneity despite similar genotypes. It also put emphasis on the significance of kidney biopsy to differentiate IgA vasculitis nephropathy from other immune disorders.
The bisnaphthalimidopropyl derivatives with anti-parasitic and anti-cancer activity. Bisnaphthalimidopropyl derivatives (A) BNIPPut, BNIPDapen, BNIPDhex, BNIPDahep, BNIPDaoct, BNIPDanon, BNTPDadec, BNIPDadod, BNPDpta, BNIPDeta were synthesized in yields ranging from 50-70 and their cytotoxicity against colon cancer cells (CaCo-2) and the parasite Leishmania infantum determined using the MTT assay and by luciferase activity present in parasite, respectively. Cytotoxicity within CaCo-2 cells was manifested with IC50 values between 0.3 and 22 m M after 48h of compounds incubation. Against Leishmania infantum, IC50 values were encompassed within a narrower concentration range of 0.39-2.09 m M, for pro- mastigote form, and between 5.24 and 17.42 m M, for axenic amastigote and between 2.43 and 9.52 m M, for intracellular amastigote forms. These compounds can be an alternative to the normal therapeutic in the fields below (A), could be a solution to the toxicity and resistance related to the compounds existent in the market. Point of diversity.
BACKGROUND: Pericytes are capillary-associated mural cells involved in the maintenance and stability of the vascular network. Although aging is one of the main risk factors for cardiovascular disease, the consequences of aging on cardiac pericytes are unknown.
METHODS: In this study, we have combined single-nucleus RNA sequencing and histological analysis to determine the effects of aging on cardiac pericytes. Furthermore, we have conducted in vivo and in vitro analysis of RGS5 (regulator of G-protein signaling 5) loss of function and finally have performed pericytes-fibroblasts coculture studies to understand the effect of RGS5 deletion in pericytes on the neighboring fibroblasts.
RESULTS: Aging reduced the pericyte area and capillary coverage in the murine heart. Single-nucleus RNA sequencing analysis further revealed that the expression of Rgs5 was reduced in cardiac pericytes from aged mice. In vivo and in vitro studies showed that the deletion of RGS5 impaired cardiac function, induced fibrosis, and morphological changes in pericytes characterized by a profibrotic gene expression signature and the expression of different ECM (extracellular matrix) components and growth factors, for example, TGFB2 and PDGFB. Indeed, culturing fibroblasts with the supernatant of RGS5-deficient pericytes induced their activation as evidenced by the increased expression of αSMA (alpha smooth muscle actin) in a TGFβ (transforming growth factor beta)2-dependent mechanism.
CONCLUSIONS: Our results have identified RGS5 as a crucial regulator of pericyte function during cardiac aging. The deletion of RGS5 causes cardiac dysfunction and induces myocardial fibrosis, one of the hallmarks of cardiac aging.
OBJECTIVE: Obesity increases osteoarthritis (OA) risk due to adipose tissue dysfunction with associated metabolic syndrome and excess weight. Lipodystrophy syndromes exhibit systemic metabolic and inflammatory abnormalities similar to obesity without biomechanical overloading. Here, we used lipodystrophy mouse models to investigate the effects of systemic versus intra-articular adipose tissue dysfunction on the knee.
METHODS: Intra-articular adipose tissue development was studied using reporter mice. Mice with selective lipodystrophy of intra-articular adipose tissue were generated by conditional knockout (cKO) of Bscl2 in Gdf5-lineage cells, and compared with whole-body Bscl2 knockout (KO) mice with generalised lipodystrophy and associated systemic metabolic dysfunction. OA was induced by surgically destabilising the medial meniscus (DMM) and obesity by high-fat diet (HFD). Gene expression was analysed by quantitative RT-PCR and tissues were analysed histologically.
RESULTS: The infrapatellar fat pad (IFP), in contrast to overlying subcutaneous adipose tissue, developed from a template established from the Gdf5-expressing joint interzone during late embryogenesis, and was populated shortly after birth by adipocytes stochastically arising from Pdgfrα-expressing Gdf5-lineage progenitors. While female Bscl2 KO mice with generalised lipodystrophy developed spontaneous knee cartilage damage, Bscl2 cKO mice with intra-articular lipodystrophy did not, despite the presence of synovial hyperplasia and inflammation of the residual IFP. Furthermore, male Bscl2 cKO mice showed no worse cartilage damage after DMM. However, female Bscl2 cKO mice showed increased susceptibility to the cartilage-damaging effects of HFD-induced obesity.
CONCLUSION: Our findings emphasise the prevalent role of systemic metabolic and inflammatory effects in impairing cartilage homeostasis, with a modulatory role for intra-articular adipose tissue.
Families who call the healthline service about a sick child and who are identified as having a danger sign will be directed to the nearest medical facility. Illness progression will be tracked with a 8-12 day follow up call.
The intervention group will perform an 8 week program, 2 sessions a week for a total of 16 sessions. training will be done on a designated negative gradient treadmill. first two session will be in -5% gradient. sessions 3,4 and 5 will be in -10% gradient, all of the following sessions will be in -15% gradient. exercise intensity will be 70%-80% out of maximal heart-rate. Session length will gradually increase by one minute each training, starting from 10 minutes at the first session, up to 25 minutes on final sessions. each training will start and end with a 2 minutes of warm up and calm down under neutral gradient. Every two minutes of training, Visual Analog Scale and Rating of Perceived Exertion data will be collected from the participants.
The present invention addresses the problem of providing means for improving the lactoferrin elution property of an enteric tablet in the intestine over time, particularly at high temperatures. One embodiment of the present invention is an enteric coated tablet comprising (A) lactoferrin and (B) crystalline cellulose, the bulk density of (B) crystalline cellulose being 0.23g/cm 3 The above. In one embodiment, the bulk density of the crystalline cellulose (B) is preferably 0.25g/cm 3 The above. Further, the weight ratio (B/a) of (B) crystalline cellulose and (a) lactoferrin is preferably 0.09 or more. In one embodiment, the weight ratio (B/a) is preferably 60 or less. Another embodiment of the present invention is a process for producing enteric-coated tablets, wherein (A) lactoferrin is incorporated and the bulk density is 0.23g/cm by a tableting machine 3 Tabletting the mixed powder of the crystalline cellulose (B) to obtain a plain tablet, and coating the plain tablet.
Tofacitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. Tofacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. JAK enzymes transmit cytokine signaling through pairing of JAKs (e.g., JAK1/JAK3, JAK1/JAK2, JAK1/TyK2, JAK2/JAK2). Tofacitinib inhibited the in vitro activities of JAK1/JAK2, JAK1/JAK3, and JAK2/JAK2 combinations with IC50 of 406, 56, and 1377 nM, respectively. However, the relevance of specific JAK combinations to therapeutic effectiveness is not known.
Patients receive vorinostat PO QD on days 1-5, ifosfamide IV continuously over 24 hours and carboplatin IV over 1 hour on day 4, and etoposide IV over 1 hour on days 3-5. Patients who are CD20+ also receive rituximab IV once on day 3, 4, or 5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.